1. Scrip
  2. >>Business
  3. >>Earnings

Pfizer's Business Development Transition: From "Revenues Now" To Pipeline Development

 
• By Jessica Merrill

Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.

NEW YORK CITY - MAY 2015: Metal plate logo of Pfizer in his headquarters building. Pfizer is an American multinational pharmaceutical corporation, one of the world's largest pharmaceutical companies.

Pfizer Inc. is reorienting its business development strategy from bringing in "revenues now" to building out the pipeline, CEO Albert Bourla said during the company's first quarter sales and earnings call April 30. The chief executive has been outspoken about his desire to avoid mega-deals since taking over as CEO Jan. 1 from Ian Read and offered a few more details on the company's business development strategy, which includes continued interest in gene therapy.

"Before we were targeting revenues now or soon … because this is what we needed at the time," Bourla said....

More from Earnings

Top 10 Drugs Q2 2025: Mounjaro Overtakes Ozempic

 
• By Eleanor Malone

Eli Lilly’s Mounjaro overtook rival GLP-1 agonist Ozempic from Novo Nordisk to become the second-highest selling drug globally in the second quarter of 2025, while overall GLP-1 drug sales continued to swell.

Stock Watch: Is First To Market Always Best?

 
• By Andy Smith

The first approved anti-PD-1 antibody to market eased ahead of later entrants by sales. But efficacy, tolerability and ease of administration are factors that count beyond first-mover advantage.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.

More from Business

Publisher’s Spotlight: Shortlist Unveiled For Citeline Japan Awards

 
• By Ian Haydock

Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!

Asia Deal Watch: Aditum Founds Kalexo With Mabwell To Develop Dual-Target SiRNA Asset

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, Vibha Ravi, and Lisa Takagi

Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.